IDEC-C2B8 data

IDPH (San Diego) reported on 18 patients in the Phase I portion of a Phase I/II study, showing that relapsed tumors shrank in 11 of the enrollees after four intravenous doses.

All patients showed rapid depletion of B cells in blood. Seven had tumor shrinkage greater than 50 percent, and four had shrinkage of at least 25 percent. Six of the seven partial responders are in remission three to seven months later. ...